Interim Report Q2 2011

Good growth in sales volume adversely affected by currency effects.

Kennet Rooth, CEO: "We had a continued positive trend in product sales in the
second quarter with strong volume growth for many products and in most markets.
Sales of Orfadin®, for example, increased by 19% after adjustment for currency
effects. Manufacturing revenues for ReFacto® in the second quarter were,
however, lower than in the previous year following large delivery volumes in the
first quarter of the year. Both revenues and profits continued to be negatively
affected by currency effects and by the mandatory price reductions implemented
in many European countries in 2010.

The rights issue was concluded during the quarter. It was fully subscribed and
has reduced net debt by SEK 594 M. Considerable effort has been put into
reducing the company's costs. Sales and administrative expenses were reduced by
12% compared to the second quarter in 2010. Cost reductions were also made in
R&D where the previously announced staff cuts, mainly in preclinical
development, are still being made. Investment in the phase III Kiobrina® study
has, however, increased costs compared to the second quarter the previous year.
The ongoing clinical development projects are continuing according to plan."

  * Sales of the existing product portfolio increased by 11% adjusted for
    currency effects.
  * Net revenues fell by 4% to SEK 490.0 M (509.6), but increased by 7% adjusted
    for currency effects and discontinued products.
  * The gross margin improved from the first quarter of the year but was lower
    than in the previous year mainly due to currency effects.
  * Operating profit was positively affected by SEK 149.2 M as a result of an
    agreement regarding Multiferon® with the previous owners of Swedish Orphan.
  * Operating profit (EBITA) before non-recurring items amounted to SEK 180.4 M
    (58.9) and to SEK 31.2 M (58.9) excluding the effect of the Multiferon®
    agreement.
  * Geoffrey McDonough appointed new President and CEO as of August 15, 2011.
  * The outlook for the full year 2011 is unchanged.



For further information, please contact:
Kennet Rooth, CEO, phone +46 8 697 38 82
Lars Sandström, CFO, phone +46 8 697 26 33

About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing specialty pharmaceuticals for patients with rare diseases and
significant medical needs. The portfolio comprises about 60 marketed products,
as well as projects in late clinical phase. Key therapeutic areas are
hematological diseases, autoimmune diseases, hereditary metabolic disorders and
therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and
approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. For more information please visit www.sobi.com

The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on July 19, 2011 at 8.30 CET.